Related Experiment Video

Updated: Aug 9, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the

Isabella Kardys1, Caroline C W Klaver, Dominiek D G Despriet

  • 1Department of Epidemiology & Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands.

Journal of the American College of Cardiology
|April 25, 2006
PubMed

Insights

The complement factor H (CFH) gene Tyr402His polymorphism increases myocardial infarction risk. This highlights the alternative complement system's role in cardiovascular disease susceptibility.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Immunology and Atherogenesis

Background:

  • Inflammation is increasingly recognized as a key factor in atherogenesis.
  • Complement factors, including complement factor H (CFH), are implicated in coronary heart disease (CHD).
  • The CFH gene regulates the alternative complement cascade, a pathway relevant to cardiovascular health.

Purpose of the Study:

  • To investigate the association between the CFH gene polymorphism (Tyr402His, rs1061170) and the risk of coronary heart disease.
  • To determine if this common genetic variation influences susceptibility to myocardial infarction.

Main Methods:

  • Prospective, population-based study (Rotterdam Study) of 5,520 participants aged 55+ without prior CHD.
  • Genotyping for the CFH Tyr402His polymorphism.
  • Cox proportional hazards analysis to assess myocardial infarction risk associated with genotypes.

Main Results:

  • The His allele frequency was 36% in the study population.
  • HisHis homozygotes exhibited a 1.77-fold increased hazard ratio for myocardial infarction after adjustments.
  • This association was modified by cholesterol levels, diabetes, and smoking, but not by CRP levels or other cardiovascular risk factors.

Conclusions:

  • The CFH gene Tyr402His polymorphism is a significant determinant of myocardial infarction susceptibility.
  • This finding emphasizes the critical role of the alternative complement system in the pathogenesis of cardiovascular disease.
Abstract

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...